Daniel J. Lippis's most recent trade in Edwards Lifesciences Corp was a trade of 4,114 Common Stock done at an average price of $79.5 . Disclosure was reported to the exchange on July 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 79.46 per share. | 28 Jul 2025 | 4,114 | 22,001 (0%) | 0% | 79.5 | 326,900 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.79 per share. | 07 Jul 2025 | 333 | 26,115 (0%) | 0% | 76.8 | 25,571 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.68 per share. | 11 May 2025 | 271 | 26,345 (0%) | 0% | 73.7 | 19,967 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 21,500 | 21,500 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 4,225 | 4,225 | - | - | Performance Rights | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 4,225 | 26,616 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 08 May 2025 | 330 | 26,946 (0%) | 0% | 45.3 | 14,941 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2025 | 330 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 74.42 per share. | 08 May 2025 | 330 | 26,616 (0%) | 0% | 74.4 | 24,560 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.65 per share. | 03 May 2025 | 247 | 22,391 (0%) | 0% | 75.7 | 18,686 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.65 per share. | 03 May 2025 | 225 | 22,638 (0%) | 0% | 75.6 | 17,021 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 08 Apr 2025 | 300 | 23,163 (0%) | 0% | 45.3 | 13,583 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2025 | 300 | 330 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 70.61 per share. | 08 Apr 2025 | 300 | 22,863 (0%) | 0% | 70.6 | 21,183 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 69.48 per share. | 10 Mar 2025 | 400 | 22,588 (0%) | 0% | 69.5 | 27,792 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 400 | 630 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 10 Mar 2025 | 400 | 22,988 (0%) | 0% | 45.3 | 18,111 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.19 per share. | 16 Feb 2025 | 222 | 22,588 (0%) | 0% | 76.2 | 16,914 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.19 per share. | 16 Feb 2025 | 214 | 22,975 (0%) | 0% | 76.2 | 16,305 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.19 per share. | 16 Feb 2025 | 165 | 22,810 (0%) | 0% | 76.2 | 12,571 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 76.34 per share. | 13 Feb 2025 | 500 | 23,189 (0%) | 0% | 76.3 | 38,170 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 500 | 1,030 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 13 Feb 2025 | 500 | 23,689 (0%) | 0% | 45.3 | 22,638 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 16 Jan 2025 | 500 | 23,689 (0%) | 0% | 45.3 | 22,638 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 68.76 per share. | 16 Jan 2025 | 500 | 23,189 (0%) | 0% | 68.8 | 34,382 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2025 | 500 | 1,530 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 16 Dec 2024 | 2,500 | 25,689 (0%) | 0% | 45.3 | 113,192 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2024 | 2,500 | 2,030 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 74.08 per share. | 16 Dec 2024 | 2,500 | 23,189 (0%) | 0% | 74.1 | 185,196 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 11 Jul 2024 | 500 | 23,689 (0%) | 0% | 45.3 | 22,638 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 500 | 4,530 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 94.18 per share. | 11 Jul 2024 | 500 | 23,189 (0%) | 0% | 94.2 | 47,090 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.32 per share. | 07 Jul 2024 | 410 | 23,189 (0%) | 0% | 92.3 | 37,851 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 535 | 5,030 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 20 Jun 2024 | 535 | 23,512 (0%) | 0% | 90 | 48,150 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 20 Jun 2024 | 535 | 24,047 (0%) | 0% | 45.3 | 24,223 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.72 per share. | 11 May 2024 | 377 | 23,512 (0%) | 0% | 86.7 | 32,693 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 15,500 | 15,500 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 4,660 | 21,575 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 2,900 | 24,475 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 2,900 | 2,900 | - | - | Performance Rights | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 07 May 2024 | 857 | 25,332 (0%) | 0% | 36.8 | 31,495 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 85.60 per share. | 07 May 2024 | 857 | 23,889 (0%) | 0% | 85.6 | 73,359 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2024 | 857 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.09 per share. | 07 May 2024 | 586 | 24,746 (0%) | 0% | 85.1 | 49,863 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.25 per share. | 03 May 2024 | 291 | 16,915 (0%) | 0% | 85.3 | 24,808 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.06 per share. | 03 May 2024 | 281 | 17,206 (0%) | 0% | 85.1 | 23,902 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 09 Apr 2024 | 857 | 18,344 (0%) | 0% | 36.8 | 31,495 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2024 | 857 | 857 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 92.34 per share. | 09 Apr 2024 | 857 | 17,487 (0%) | 0% | 92.3 | 79,135 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Sale of securities on an exchange or to another person at price $ 90.98 per share. | 07 Mar 2024 | 1,715 | 17,213 (0%) | 0% | 91.0 | 156,031 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 1,715 | 1,714 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 07 Mar 2024 | 1,715 | 18,928 (0%) | 0% | 36.7 | 63,026 | Common Stock |
| Edwards Lifesciences | Lippis Daniel J. | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.04 per share. | 16 Feb 2024 | 207 | 17,551 (0%) | 0% | 86.0 | 17,810 | Common Stock |
| Edwards Lifesciences | J. Lippis Daniel | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.10 per share. | 16 Feb 2024 | 188 | 17,213 (0%) | 0% | 86.1 | 16,187 | Common Stock |
| Edwards Lifesciences | Daniel J. Lippis | CVP, JAPAC | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.10 per share. | 16 Feb 2024 | 150 | 17,401 (0%) | 0% | 86.1 | 12,915 | Common Stock |